182 related articles for article (PubMed ID: 12621103)
1. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
Senzaki H; Kobayashi T; Nagasaka H; Nakano H; Kyo S; Yokote Y; Sasakid N
Pediatr Res; 2003 Jun; 53(6):983-8. PubMed ID: 12621103
[TBL] [Abstract][Full Text] [Related]
2. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions].
Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276
[TBL] [Abstract][Full Text] [Related]
3. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease.
Ikeda K; Ihara K; Yamaguchi K; Muneuchi J; Ohno T; Mizuno Y; Hara T
Pediatr Res; 2008 Feb; 63(2):182-5. PubMed ID: 18091353
[TBL] [Abstract][Full Text] [Related]
5. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
6. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
7. S100A12 on circulating endothelial cells surface in children with Kawasaki disease.
Fu S; Gong F; Xie C; Zhu W; Wang W; Shen H; Tang Y
Pediatr Res; 2010 Aug; 68(2):165-8. PubMed ID: 20461025
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of vascular endothelial growth factor in Kawasaki disease.
Maeno N; Takei S; Masuda K; Akaike H; Matsuo K; Kitajima I; Maruyama I; Miyata K
Pediatr Res; 1998 Oct; 44(4):596-9. PubMed ID: 9773852
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of vascular leakage in acute Kawasaki disease.
Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
[TBL] [Abstract][Full Text] [Related]
11. Arterial hemodynamics in patients after Kawasaki disease.
Senzaki H; Chen CH; Ishido H; Masutani S; Matsunaga T; Taketazu M; Kobayashi T; Sasaki N; Kyo S; Yokote Y
Circulation; 2005 Apr; 111(16):2119-25. PubMed ID: 15851619
[TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease.
Furuno K; Takada H; Yamamoto K; Ikeda K; Ohno T; Khajoee V; Mizuno Y; Hara T
J Pediatr; 2007 Aug; 151(2):155-60, 160.e1. PubMed ID: 17643768
[TBL] [Abstract][Full Text] [Related]
13. Association of COL11A2 polymorphism with susceptibility to Kawasaki disease and development of coronary artery lesions.
Sheu JJ; Lin YJ; Chang JS; Wan L; Chen SY; Huang YC; Chan C; Chiu IW; Tsai FJ
Int J Immunogenet; 2010 Dec; 37(6):487-92. PubMed ID: 20618517
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y
Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369
[TBL] [Abstract][Full Text] [Related]
15. [Changes of P-selectin and E-selectin in children with Kawasaki disease].
Qiu Y; Wu J; Fang XY; Lin Z; Wu BY; Cai RY; Xu XY; Zheng H
Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):688-92. PubMed ID: 15482673
[TBL] [Abstract][Full Text] [Related]
16. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
17. Histo-blood group gene polymorphisms as potential genetic modifiers of the development of coronary artery lesions in patients with Kawasaki disease.
Yamamura K; Ihara K; Ikeda K; Nagata H; Mizuno Y; Hara T
Int J Immunogenet; 2012 Apr; 39(2):119-25. PubMed ID: 22117627
[TBL] [Abstract][Full Text] [Related]
18. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.
Senzaki H
Arch Dis Child; 2006 Oct; 91(10):847-51. PubMed ID: 16990356
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
20. Association between adropin and coronary artery lesions in children with Kawasaki disease.
Yang M; Pei Q; Zhang J; Weng H; Jing F; Yi Q
Eur J Pediatr; 2021 Jul; 180(7):2253-2259. PubMed ID: 33712900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
